Disease-free survival did not improve with two years of celecoxib versus placebo in ERBB2-negative breast cancer<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
<\/a>FRIDAY, July 16, 2021 (HealthDay News) — For patients with ERBB2-negative breast cancer, two years of treatment with celecoxib as adjuvant to conventional therapy yields no disease-free survival (DFS) benefits compared with placebo, according to a study published online July 15 in JAMA Oncology<\/em>.<\/p>\n R. Charles Coombes, M.D., Ph.D., from Imperial College London, and colleagues conducted a randomized trial in 160 centers testing two years of adjuvant celecoxib versus placebo among 2,639 patients with ERBB2 (formerly HER2)-negative breast cancer. Participants were randomly assigned to either celecoxib or placebo in a 2:1 ratio (1,763 and 876, respectively).<\/p>\n Overall, 73 percent of the tumors were estrogen receptor-positive or progesterone receptor-positive and ERBB2-negative. Forty-eight percent of patients had node-positive disease and 42 percent had grade 3 tumors. The researchers found that DFS events were reported for 487 patients (19 percent) at a median follow-up of 74.3 months: 18 and 19 percent for those who received celecoxib and placebo, respectively (five-year DFS rates, 84 and 83 percent, respectively), with an unadjusted hazard ratio of 0.97 (95 percent confidence interval, 0.80 to 1.17; log-rank P = 0.75). Across both treatment groups, the rates of toxic effects were low, with no evidence of a difference.<\/p>\n “Despite compelling preclinical and observational evidence suggesting a role for anti-inflammatory agents in the management of breast cancer, celecoxib failed to reduce the risk of recurrence or mortality among individuals with early-stage disease,” write the authors of an accompanying editorial.<\/p>\n Several authors disclosed financial ties to biopharmaceutical companies, including Pfizer, which manufactures celecoxib and partially funded the study.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n